Kura Oncology officer proposes roughly $26K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kura Oncology, Inc. officer Kathleen Ford reported a proposed sale of 3,668 common shares, with an approximate market value of $26,006.12 and an approximate sale date of November 17, 2026. Ford acquired the shares from the issuer as performance stock units on November 13, 2026.
During the prior three months, Ford reported sales of 7,042 shares for gross proceeds of $52,421.35 on November 16, 2026; 3,668 shares for $39,436.87 on September 29, 2026, listed as a 10b5-1 sale; and 6,906 shares for $72,494.35 on September 27, 2026. The reported Rule 10b5-1 plan adoption or instruction date is May 29, 2026.
Key Figures
Key Terms
Performance Stock Units financial
Rule 10b5-1 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.